Oral Anticoagulation Continuation Throughout TAVR: High Risk-High Reward or Marginal Gains?
作者信息
Auffret Vincent, Leurent Guillaume, Le Breton Hervé
机构信息
Université de Rennes 1, CHU Rennes Service de Cardiologie, Inserm LTSI U1099, France.
Université de Rennes 1, CHU Rennes Service de Cardiologie, Inserm LTSI U1099, France.
出版信息
JACC Cardiovasc Interv. 2021 Jan 25;14(2):145-148. doi: 10.1016/j.jcin.2020.10.026. Epub 2020 Dec 23.
PMID:33358646
Abstract
摘要
相似文献
1
Oral Anticoagulation Continuation Throughout TAVR: High Risk-High Reward or Marginal Gains?经导管主动脉瓣置换术全程口服抗凝治疗：高风险-高回报还是微不足道的获益？
JACC Cardiovasc Interv. 2021 Jan 25;14(2):145-148. doi: 10.1016/j.jcin.2020.10.026. Epub 2020 Dec 23.
2
Oral Anticoagulants After Transcatheter Aortic Valve Replacement: Another Home Run for Direct Oral Anticoagulants?经导管主动脉瓣置换术后的口服抗凝药：直接口服抗凝药的又一成功之举？
JACC Cardiovasc Interv. 2020 Nov 23;13(22):2598-2600. doi: 10.1016/j.jcin.2020.10.009.
3
Safety and Efficacy of Transcatheter Aortic Valve Replacement With Continuation of Vitamin K Antagonists or Direct Oral Anticoagulants.维生素K拮抗剂或直接口服抗凝剂持续使用情况下经导管主动脉瓣置换术的安全性和有效性
JACC Cardiovasc Interv. 2021 Jan 25;14(2):135-144. doi: 10.1016/j.jcin.2020.09.062. Epub 2020 Dec 23.
4
Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后口服抗凝药物类型与结局。
JACC Cardiovasc Interv. 2019 Aug 26;12(16):1566-1576. doi: 10.1016/j.jcin.2019.03.003. Epub 2019 Jun 12.
5
Anticoagulation After Transcatheter Aortic Valve Replacement: Evolving Answers and Still Unaddressed Questions.经导管主动脉瓣置换术后的抗凝治疗：不断演变的答案与仍未解决的问题
JACC Cardiovasc Interv. 2021 Aug 9;14(15):1714-1716. doi: 10.1016/j.jcin.2021.06.004. Epub 2021 Jul 14.
6
What Oral Anticoagulant Is Best After TAVR: Vitamin K Antagonists or Direct Oral Anticoagulants?经导管主动脉瓣置换术后哪种口服抗凝剂最佳：维生素K拮抗剂还是直接口服抗凝剂？
JACC Cardiovasc Interv. 2024 Feb 12;17(3):419-421. doi: 10.1016/j.jcin.2023.12.024.
7
Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management.主动脉瓣狭窄的挑战：经导管主动脉瓣置换术（TAVR）治疗中抗血小板/抗凝管理的回顾：近期 PCI 合并 TAVR、心房颤动患者的 TAVR 以及 TAVR 血栓管理。
Curr Cardiol Rep. 2018 Oct 11;20(12):130. doi: 10.1007/s11886-018-1073-9.
8
Adjuvant Antithrombotic Therapy in TAVR.经导管主动脉瓣置换术（TAVR）中的辅助抗血栓治疗
Curr Cardiol Rep. 2017 May;19(5):41. doi: 10.1007/s11886-017-0850-1.
9
Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.华法林和抗血小板治疗与华法林单药治疗行经导管主动脉瓣置换术的心房颤动患者。
JACC Cardiovasc Interv. 2016 Aug 22;9(16):1706-17. doi: 10.1016/j.jcin.2016.06.025.
10
Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series.经导管主动脉瓣置换术后直接口服抗凝剂的应用：病例系列。
J Cardiovasc Pharmacol. 2020 Jan;75(1):41-44. doi: 10.1097/FJC.0000000000000755.
引用本文的文献
1
Outcomes of periprocedural continuation interruption of oral anticoagulation in transcatheter aortic valve replacement.经导管主动脉瓣置换术中围手术期口服抗凝药持续使用或中断的结局
World J Cardiol. 2025 Mar 26;17(3):104000. doi: 10.4330/wjc.v17.i3.104000.
Zotero 插件